1. Cybin will participate in a summit on neuropsychiatry on September 17, 2025. 2. Key executives will discuss innovative treatment options for mental health. 3. Cybin is developing drugs like CYB003 and CYB004 for mental health disorders. 4. CYB003 has received FDA's Breakthrough Therapy Designation for depression. 5. Cybin aims to revolutionize mental healthcare with novel treatment options.
Participation in events increases visibility, potentially driving investor interest. Historical analysis shows presentations at industry conferences can positively impact stock prices of biotech firms.
The announcement enhances CYBN's profile in the neuropsychiatry field, attracting potential investments. Continued pipeline developments and earnings reports can further validate stock performance.
The development timeline for drugs usually leads to long-term impacts on stock price. Previous cases, like those of other biotech firms, illustrate sustained interest from investors following positive conference presentations.
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Amir Inamdar, Cybin's Chief Medical Officer, and George Tziras, Cybin's Chief Business Officer, will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Wednesday, September 17, 2025, at 9:20 a.m. ET.
The webcast and replay will be available on the Company's investor relations website on the Events & Presentations page.
About Cybin
Cybin® is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250911135365/en/
Investor Contact:
Candice Masse
astr partners
Managing Director
(978) 879-7273
candice.masse@astrpartners.com
Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com